Recent evidence suggests that postischemic myocardial dysfunction ("stunning") may be mediated by oxygen free radicals, but the exact time window during which the critical radical-mediated damage develops remains unknown. Furthermore, the evidence for the oxyradical hypothesis is indirect and, therefore, inconclusive. Thus, the potent and cellpermeable antioxidant JV-(2-mercaptopropionyl)-glycine (MPG) was administered as an intracoronary infusion (8 mg/kg/hr) to three groups of open-chest dogs undergoing a 15-mlnute coronary occlusion followed by 4 hours of reperfusion. In group I (n=8), the infusion of MPG was started 15 minutes before occlusion and ended 2 hours after reperfusion; in group II (n=9), MPG was started 1 minute before reperfusion and ended 2 hours thereafter; in group III (/i = 10), MPG was started 1 minute after reperfusion and ended 2 hours and 15 minutes thereafter. Control dogs (group IV) (n = 10) received vehicle. Recovery of contractile function (assessed as systolic wall thickening) was equivalent in groups I and II, and in both groups it was substantially greater than in controls (p<0.005 at 4 hours). In contrast, in group III recovery of function was indistinguishable from controls. To determine whether the protection afforded by MPG was due to inhibition of free radical reactions, myocardial production of free radicals was directly assessed by intracoronary infusion of the spin trap o-phenyl JV-tert-butyl nitrone (PBN). In control dogs (group VII, n=6), radical adducts of PBN were released in the coronary venous blood after reperfusion, with a burst occurring in the first 5 minutes. MPG given as in group II (group V, n-5) markedly suppressed myocardial production of PBN adducts ( A --9 8 % over 3 hours, /?<0.01 vs. controls); this effect was evident immediately after reperfusion. MPG given as in group III (group VI, n=5) also suppressed PBN adduct production (A =-83% over 3 hours,p<0.025 vs. controls), but this effect was delayed. Hence, the radicals important in myocardial stunning appear to be those generated immediately after reperfusion. In vitro studies demonstrated that MPG is an exceptionally powerful scavenger of • OH (rate constant=8.1x10* M~'sec~' by pulse radiolysis) but has no significant effect on • O7 (rate constant <10 3 M"'sec"'), H 2 O 2 (rate constant=1.6 M" 1 sec" 1 ), or non-• OH-initiated lipid peroxidation, suggesting that removal of • OH is the major mechanism of the beneficial effects of MPG. These results demonstrate that a substantial portion (apparently most) of the damage responsible for myocardial stunning develops in the initial seconds of reperfusion and can be prevented by antioxidant therapy started just before reftow. The results further demonstrate that attenuation of this reperfusion-induced damage is associated with attenuation of free radical reactions in vivo, thereby providing direct evidence for a causal role of reactive oxygen species. It is proposed that myocardial stunning is, at least in part, a form of oxyradicalmediated "reperfusion injury.
M yocardium reperfused after brief, reversible ischemia exhibits prolonged depression of contractile function 1 -4 or "stunning," 5 which is associated with a variety of ultrastructural, metabolic, vascular, electrophysiological, and other functional abnormalities. 1 -7 Recent studies have shown that myocardial stunning can be attenuated by antioxidants, 8 -14 suggesting that the accumulation of reactive oxygen metabolites, such as superoxide radical (• Oj), hydrogen peroxide (H 2 O 2 ), and hydroxyl radical (• OH), may play an important role in the pathogenesis of postischemic contractile dysfunction. Several fundamental questions, however, remain unanswered and must be addressed before the free radical hypothesis can be definitively accepted and effective clinical therapies can be developed.
First, does the critical free radical-mediated damage take place during ischemia, after reperfusion, or both? The aforementioned studies did not elucidate this issue because they evaluated the effect of antioxidants administered before coronary occlusion. 8 -14 Oxyradical injury could theoretically occur during ischemia because relatively low oxygen tensions are sufficient to generate reactive oxygen species 1516 and the collateral circulation present in the canine (and probably human) heart is sufficient to achieve such tensions. 15 ' 17 Indeed, it has been calculated that a collateral flow of 10% of normal (which is less than that observed in the canine ischemic subepicardium) will provide sufficient oxygen to saturate the xanthine oxidase reaction. 17 The concept that free radical injury may occur during ischemia is supported by studies showing reduction of infarct size with antioxidant agents administered in the setting of a permanent coronary occlusion. 17 - 18 Furthermore, we recently demonstrated, in our canine model of myocardial stunning produced by a 15-minute coronary occlusion, that free radicals are generated not only after but also during ischemia. 19 Second, if the critical free radical-mediated damage starts after reperfusion, what is the exact time window during which it develops? In the aforemen-tioned study it was found that production of free radicals continues for at least 3 hours after reflow. 19 Therefore, it is possible that reperfusion may be associated with prolonged radical-mediated damage and that antioxidant therapy given after reperfusion may still be beneficial.
The third question is critical to the investigation of the foregoing problems and to the entire concept that reperfusion injury is mediated by free radicals: if antioxidant agents given only at the time of reperfusion are protective, is such protection actually due to inhibition of free radical reactions? Although many studies have demonstrated beneficial effects of antioxidants in the stunned myocardium, 8 -14 the mechanism of such effects has not been conclusively established. As a consequence, unequivocal demonstration of a causal role of oxygen metabolites has not been possible. The major problem is that thus far anti-free radical activity has been assumed to occur in vivo without direct evidence because the antioxidants that attenuate stunning have not been proven to scavenge radicals in a complex system such as the intact animal. Undoubtedly, the indirect nature of the evidence available is the major reason why to date the free radical hypothesis of myocardial stunning remains controversial.
Fourth, if reperfusion injury is mediated by oxygen radicals, which species (• Oj, H 2 O 2 , or • OH) is actually responsible for production of this injury?
The present study had three objectives. The first objective was to precisely identify the time interval during which the critical free radical-mediated damage responsible for stunning occurs. To this end, the potent and cell-permeable free radical scavenger yV-(2-mercaptopropionyl)-glycine (MPG) was administered at different times (i.e., starting before ischemia, at reperfusion, or shortly after reperfusion), and the effects of these various treatments were compared. The second objective was to determine whether attenuation of myocardial stunning by MPG is associated with attenuation of free radical reactions in the intact animal. To this end, generation of free radicals in the stunned myocardium was directly measured by use of the spin trap a-phenyl 7v*-fe/?-butyl nitrone (PBN) and electron paramagnetic resonance (EPR) spectroscopy in the presence and absence of MPG. The third objective was to carefully define the ability of MPG to scavenge different oxidants in vitro to gain insights into the relative roles of such oxidants in the pathogenesis of myocardial stunning. To this end, the rate constants for the reactions of MPG with • Oj, H 2 O 2 , and • OH were measured and compared.
Materials and Methods
A total of 82 dogs were used. The experimental preparation and techniques have been previously described in detail. 8.11-14,19-21 
Phase A: Studies of the Effect of MPG on Recovery of Contractile Function
Experimental preparation. Dogs of either sex (16-34 kg) were anesthetized with sodium pentobarbital (35 mg/kg i.v.). Instruments were placed as follows: a snare and a Doppler flow probe around the mid-left anterior descending coronary artery (LAD), epicardial Doppler wall thickening probes 22 on the region to be rendered ischemic and on the posterior (control) left ventricular (LV) wall, catheters in the aorta and left atrium, and a pressure transducer (Millar Instruments, Houston, Texas) in the LV cavity. A 27-gauge needle connected to a lymphangiographic catheter 19 was introduced into the LAD, just distal to the snare, for infusion of MPG or vehicle. For prevention of clotting, heparin (3,000 units i.v.) was given immediately after insertion of the needle and continuously thereafter (500 units/hr). Particular care was taken to ensure that fundamental physiological parameters (temperature and arterial pH, PO2, and hematocrit) were within normal limits for the entire duration of the protocol. 14 Supplements of potassium chloride (20 meq) were given intravenously to maintain plasma potassium concentration in the range of 4.0-5.0 meq/1. 1 * The rate of fluid replacement was standardized at ~80 ml normal saline/hr. 19 Experimental protocol. All treated dogs received an intracoronary infusion of MPG (Sigma Chemical, St. Louis, Missouri) at a dose of 8 mg/kg/hr. MPG was dissolved at a concentration of 10 mg/ml in a mixture of 77% heparinized normal saline and 23% water, so that the infusate was isosmotic with the plasma (osmolality=280 mosm/kg). The volume of solution infused averaged 0.30 ml/min (range: 0.21-0.45 ml/min). Before and after MPG administration, the LAD was infused with an equivalent volume of vehicle. Dogs were assigned to four treatment groups. In group I the infusion of MPG was started 15 minutes before coronary occlusion and ended 2 hours after reperfusion. During occlusion, the rate of infusion was decreased by 50% to prevent the coronary arterial concentration of MPG from rising to levels severalfold higher than those attained in groups II and III (which would have complicated comparisons). The preocclusion rate of MPG infusion was restarted 1 minute before reperfusion. In group II the infusion of MPG was started 1 minute before reperfusion and ended 2 hours thereafter. In group III the infusion of MPG was started 1 minute after reperfusion and ended 2 hours and 15 minutes thereafter. Group IV (control group) received equivalent volumes of vehicle. The intracoronary route and the dose of MPG were selected to ensure that a) high concentrations of the drug were present in the LAD bed in the initial critical moments of reperfusion when the infusion was started 1 minute before release of occlusion (group II), and b) high local MPG concentrations were maintained throughout ischemia (group I) and reperfusion (groups I, II, and III).
The LAD was occluded for 15 minutes and reperfused for 4 hours. Regional myocardial blood flow was determined 10 minutes after occlusion with radioactive microspheres. 3 Regional myocardial function was assessed as systolic thickening fraction (i.e., systolic wall thickening/end-diastolic thickness x 100) using a pulsed Doppler epicardial probe, as previously described. 3.8,11-14,19-23 7j, e occluded coronary vascular bed was identified by postmortem perfusion, 14 after which transverse slices of the heart were incubated in 1% triphenyltetrazolium chloride. 24 
Phase B: Studies of the Effect of MPG on Free Radical Production In Vivo
Experimental preparation. The experimental preparation was similar to that used in phase A, with two differences. First, to facilitate positioning of the coronary venous catheter (see below), the posterior descending or the obtuse marginal coronary artery was occluded instead of the LAD. (As in phase A, the site of occlusion was carefully selected to ensure that no branches were present between the snare and the needle or between the needle and the flow probe.) Second, a No. 8F Sones catheter (USCI Division, C.R. Bard, Inc, Billerica, Massachusetts) was introduced into the coronary sinus and advanced into the vein that accompanied the artery to be occluded (i.e., the posterior interventricular or the left marginal vein). In its final position, the tip of the catheter was at least 0.5 cm distal to the intracoronary needle, so that any contamination of blood samples with venous effluent from other vascular beds was minimized.
Experimental protocol. The selected coronary artery was occluded for 15 minutes and reperfused for 3 hours. PBN (Sigma Chemical) was infused directly into the occluded coronary artery starting 20 seconds before and ending 10 minutes after reperfusion. PBN was dissolved at a concentration of 5 mg/ml in a mixture of 80% normal saline and 20% water, so that the infusate was isosmotic with the plasma (osmolality=284 mosm/kg). Because flow in the artery to be occluded varied from dog to dog, the rate of PBN infusion was normalized to flow, so as to achieve the same concentration of PBN (285 /xg/ml or 1.6 mM) in the coronary arterial blood in all dogs. 19 Baseline coronary blood flow ranged from 12.6 to 42.3 ml/min; the rate of PBN infusion varied accordingly from 3.7 to 12.0 mg/min (mean = 7.0 mg/min). The volume of solution infused (which ranged from 0.7 to 2.4 ml/min) was equal to 6% of coronary blood flow in all dogs. All animals were given PBN as described above and were assigned to three treatment groups. Group V received MPG at the same dose previously used in phase A for group II, that is, 8 mg/kg/hr starting 1 minute before reperfusion and ending 2 hours thereafter. Group VI received MPG at the same dose previously used in phase A for group III, that is, 8 mg/kg/hr starting 1 minute after reperfusion and ending 2 hours and 15 minutes thereafter. MPG and PBN were infused through the same intracoronary needle by use of two separate infusion pumps and a four-way stopcock. Group VII (control group) received equivalent volumes of the vehicle used for MPG.
EPR analysis. Blood samples (6 ml) were drawn over 60 seconds from the aorta or from the appropriate coronary vein and immediately centrifuged. The plasma specimens were frozen at -70° C for subsequent analysis by EPR spectroscopy. The techniques used for detection of spin adducts of free radicals and quantification of the myocardial release of these species into the coronary venous effluent blood have been described in detail. 19 -25 -28 The myocardial production of spin adducts at a specific time point was expressed in arbitrary units per minute per gram of reperfused myocardium (u/min/g) 19 ; the total cumulative myocardial production of PBN adducts over a given interval was calculated by integration of the measurements obtained at individual time points. 19 Effect of MPG on PBN adducts in vitro. Four additional dogs underwent the same protocol as group VII. In each dog, four 12-ml plasma samples were collected after reflow; one half of the samples were processed as usual, whereas MPG was added to the other half to a concentration of 3.0 mg/ml (18.4 mM).
Phase C: Studies of the Effects of MPG In Vitro
Assay for superoxide radical. Generation of • Oj by the hypoxanthine-xanthine oxidase system was carried out as previously described. 29 Reaction mixtures contained, in a final volume of 3 ml, 0.1 ml of 30 mM EDTA, 10 ^1 of 30 mM hypoxanthine, 100 /xl of 3-mM cytochrome c or 3 mM nitro blue tetrazolium (NBT), and 50 mM (final concentration) of KH 2 PO 4 -KOH buffer (pH 7.4). The reaction was started by addition of 0.2 ml of xanthine oxidase (freshly diluted in phosphate buffer to give 1 unit/ml).
Assay for hydrogen peroxide. Initial attempts to measure the rate of reaction of MPG with H 2 O 2 by a peroxidase-based assay method failed because MPG was found to be a substrate for horseradish peroxidase. Hence, MPG and H 2 O 2 at various concentrations were incubated in a 5-ml reaction mixture containing 1.5 ml of 100 mM KH 2 PO 4 -KOH buffer (pH 7.4) for various times at 37° C. At intervals, 0.25-ml aliquots were added to another reaction mixture containing 2.5 ml buffer and 0.25 ml of 6 mM dithiobis (2-nitrobenzoic acid) (DTNB). AOJ was measured after 5 minutes, and the MPG concentration remaining was determined from a calibration curve. Am was proportional to MPG concentrations up to 3 mM in the DTNB assay mixture.
Assay for hydroxyl radical. The method has been detailed previously. 30 Potassium thiocyanate (KCNS) was carefully dried in an oven overnight before use.
Pulse radiolysis was performed by use of the Paterson laboratories linear accelerator facility at Manchester University, England. 31 MPG was dissolved in 10 mM KH 2 PO 4 -KOH buffer (pH 7.0) immediately before use.
Assay for lipid peroxidation. Peroxidation of ox-brain phospholipid liposomes in the presence of Fe 2+ or Fe 3+ and ascorbate, or of rat liver microsomes in the presence of Fe 2+ -ADP, Fe 3+ / ascorbate, or Fe 3+ -ADP and reduced nicotinamide adenine dinucleotide phosphate (NADPH), was measured by the thiobarbituric acid method as described previously. 32 
Statistical Analysis
All values are reported as mean±SEM. Analysis of variance was used for comparison of means among different groups of dogs and for analysis of intragroup variation. If the F test showed an overall difference, pairwise comparisons were performed with the two-tailed Student's t test for unpaired or paired data, as appropriate, and the resulting p values were adjusted by the Bonferroni method. 33 Myocardial production of PBN adducts was analyzed by nonparametric methods (Kruskall-Wallis test and Wilcoxon signed rank test) because these data did not follow a normal distribution. 33 The correlation between myocardial production of PBN adducts and collateral flow was assessed by linear regression analysis with the least-squares method.
Results

Phase A: Effect of MPG on Recovery of Contractile Function
Of the 62 dogs initially anesthetized in phase A, 25 (40%) were excluded for the reasons specified in Table 1 . Thus, analysis of data was carried out in 10 control dogs (group IV) and in eight, nine, and 10 dogs in groups I, II, and III, respectively. Tetrazolium staining confirmed the absence of irreversible tissue damage in all animals, in accordance with previous studies. 1 -3 - 6 Arterial blood gases, hematocrit, temperature, and pentobarbital dose. As shown in Tables 2 and  3 , arterial pH, Po 2 , hematocrit, and body temperature were within physiological limits in all four groups (I, II, III, and IV) throughout the experimental protocol. The total supplemental doses of pentobarbital given to maintain anesthesia were similar: 10.0±1.6, 8.8+1.4, 9.5±1.1, and 8.5±1.1 mg/kg in groups I, II, III, and IV, respectively.
Hemodynamic variables, occluded bed size, and myocardial blood flow. The administration of MPG did not produce any appreciable hemodynamic alteration (Table 4 ). Throughout the study, there were no significant hemodynamic differences among the four groups, with the exception of diastolic arterial pressure, which was slightly lower in group II versus group IV at 30 minutes and 2 hours after reperfusion (/?<0.05), and in group II versus group Table 4 ). The size of the occluded vascular bed (expressed as percent of LV weight) was larger in group II (25.3±1.8%) as compared with controls (group IV, 17.4±0.9%) (p<0.01), but did not differ among groups I, II, and III ( Table 5 ). The four groups were similar with respect to blood flow to both the ischemic and nonischemic zones ( Table 5) .
Regional myocardial function. Systolic thickening fraction in the nonischemic (control) region did not differ significantly among the four groups at any time point during the protocol (Table 4 ). Baseline systolic thickening fraction in the region to be rendered ischemic was 22±2% in group I, 24±2% in group II, 21 ±2% in group III, and 24 ±2% in group IV (p = NS). During coronary occlusion, the extent of paradoxical systolic thinning was also similar in the four groups ( Figure 1 ). After reperfusion, control dogs (group IV) exhibited little recovery of contractile function, and 4 hours after restoration of flow the previously ischemic region was still dyskinetic, indicating severe myocardial stunning. However, in group I, which received MPG beginning 15 minutes before occlusion, recovery of function was substantially greater throughout the 4-hour observation period ( Figure 1 ). In group II, which received MPG starting 1 minute before reperfusion, recovery of function was also substantially greater than in Data are mean±SEM. HR, heart rate; SAP, systolic arterial pressure; DAP, diastolic arterial pressure; RPP, rate-pressure product (heart ratexsystolic blood pressure/1,000); LAP, mean left atrial pressure; LV dP/dt^,, maximal rate of left ventricular pressure rise; LV dP/dtmj,,, maximal rate of left ventricular pressure fall; %ThF (NIZ), percent thickening fraction in nonischemic zone.
•In group I (n=8), infusion of MPG was started 15 minutes before ischemia and continued until 2 hours after reperfusion; in group II (n=9), infusion of MPG was started 1 minute before reperfusion and continued for 2 hours; in group III (n = 10), infusion of MPG was started 1 minute after reperfusion and continued for 2 hours and 15 minutes; in group IV (n = 10), no MPG was given.
1p<0.05 vs. group IV. tp<0.05 vs. group III.
controls, and essentially equivalent to that observed in group I. In contrast, in group III, which received MPG beginning 1 minute after reperfusion, recovery of function was minimal, and the previously ischemic myocardium remained dys-kinetic up to 4 hours after reflow; in these dogs thickening fraction was indistinguishable from controls (group IV) ( Figure 1 ). Statistical analysis demonstrated that throughout reperfusion (i.e., at 1, 2, 3, and 4 hours), the measurements of thick- ening fraction in groups I and II were significantly greater than the corresponding values in both groups III and IV (Figure 1 ).
Phase B: Effect of MPG on Free Radical Production In Vivo
Of the 20 dogs initially anesthetized in phase B, four (20%) were excluded for the reasons specified in Table 1 . Thus, analysis of data was carried out in six control dogs (group VII) and in five dogs in both group V and group VI. As in phase A, tetrazolium staining confirmed the absence of irreversible injury in all animals.
Arterial blood gases, hematocrit, temperature, and pentobarbital dose. As shown in Tables 2 and  3 , these variables were within physiological limits throughout the study in all three groups (V, VI, and VII). The total supplemental doses of pentobarbital were similar: 12.0±1.2, 10.5±1.5, and 10.9±l.l mg/kg in groups V, VI, and VII, respectively.
Hemodynamic variables, occluded bed size, and myocardial blood flow. Heart rate was slightly Data are mean±SEM. HR, heart rate; SAP, systolic arterial pressure; DAP, diastolic arterial pressure; RPP, rate-pressure product (heart rate X systolic blood pressure/1,000); LAP, mean left atrial pressure; CBF, coronary blood flow in artery infused with PBN; LV dP/dtnu,, maximal rate of left ventricular pressure rise; LV dP/dt^,,, maximal rate of left ventricular pressure fall.
*In group V (n=5), infusion of MPG was started 1 minute before reperfusion and continued for 2 hours; in group VI (n = 5), infusion of MPG was started 1 minute after reperfusion and continued for 2 hours and 15 minutes, in group VII (controls, n -6), no MPG was given. tp<0.05 vs. group VII (controls). &j<0.05 vs. group V.
higher in group VI than in group VII 1 hour after reperfusion, whereas systolic and diastolic arterial pressures were slightly lower in groups V and VI as compared with group VII 2 and 3 hours after reperfusion ( Table 6 ). There were no other significant hemodynamic differences between the control and the two MPG-treated groups at any time point during the protocol (Table 6 ). Groups V, VI, and VII were similar with respect to both occluded bed size and collateral blood flow ( Table 5) . Myocardial production of PBN adducts. Figure  2 shows examples of the EPR signals observed, whereas Figure 3 summarizes the time course of release of PBN adducts from the ischemic/ reperfused region in groups V, VI, and VII. In group VII (controls), EPR signals characteristic of radical adducts of PBN appeared in the coronary venous effluent immediately after reperfusion (Figures 2 and 3) . The release of PBN adducts exhibited an initial burst peaking 4 minutes after reperfusion and then declined substantially but continued up to 3 hours thereafter (Figures 2 and  3 ). No EPR signals were observed in any of the arterial blood samples (which were obtained 1,5, 20, 60, and 180 minutes into the reperfusion phase), indicating that the presence of EPR signals in the venous blood cannot be ascribed to recirculation of the PBN adducts. In group V, which received MPG beginning 1 minute before reperfusion, PBN adduct production was substantially reduced as compared with control dogs (group VII) (Figures 2 and 3 ). This effect was evident immediately after release of coronary occlusion (A=-92% \p<0.005] in the initial 60 seconds of reflow) (Figure 3 ). In the first 5 minutes of reperfu-sion (interval corresponding to the burst of spin adduct production), the total cumulative release of PBN adducts was decreased by 89% (45.8±30.8 units/g vs. 433.4±91.1 units/g in group VII,/><0.02). In contrast with group VII, in which production of spin-trapped radicals continued for 3 hours, in group V radical production ceased completely by 10 min- utes (Figures 2 and 3) . The total cumulative adduct release during the 3 hours of reperfusion was decreased by 98% (83±58 units/g in group V vs. 3,721±1,386 units/g in group VII,/?<0.01).
In both group V and group VII, there was an inverse, linear relationship between myocardial production of PBN adducts after reperfusion and collateral flow to the ischemic region during occlusion. For example, in control dogs (group VII) collateral flow correlated with the total amount of adducts released during the first 5 minutes of reperfusion (r=-0.78) and during the entire 3hour reperfusion period (r=-0.58) (Figure 4 ). Treatment with MPG greatly decreased the slope of this correlation, so that at any given level of ischemic zone flow, there was less production of PBN adducts (Figure 4) . Importantly, the effect of MPG was relatively more pronounced in the lowflow range (Figure 4) . Thus, the greater the severity of ischemia (and hence the propensity to generate radicals upon reperfusion), the greater the protection afforded by MPG.
In group VI, which received MPG beginning 1 minute after reperfusion, PBN adduct production before the start of MPG infusion (i.e., in the initial 60 seconds of reflow) was, as expected, similar to that observed in control dogs (group VII) and significantly (p<0.05) greater than that measured in group V (Figure 3 ). However, after the administra-tion of MPG, the release of spin-trapped radicals decreased rapidly. By 5 minutes of reperfusion, it was reduced to less than 50% of that observed in group VII (p<0.10), and by 10 minutes it was almost totally abolished (6±7 units/min/g vs. 61±26 units/min/g in group VII, p<0.05). By 1 hour, radical production had ceased completely ( Figure  3 ). The total cumulative adduct release during the 3 hours of reperfusion was decreased by 83% (626 ±334 units/g in group VI vs. 3,721 ±1,386 units/g in group VII, p<0.025). In summary, production of spintrapped radicals was markedly inhibited by MPG both in group V and group VI; the difference between the two groups was that this inhibition began in the initial seconds of reperfusion in group V, whereas it was delayed in group VI.
Effect of MPG on PBN adducts in vitro. In vitro addition of MPG to 16 plasma samples containing PBN adducts produced no discernible effect on the intensity of the EPR signals (data not shown), despite the fact that the concentration of MPG in these samples (3.0 mg/ml [18.4 mM] ) was approximately 120-fold higher than the calculated concentration of MPG (-25 Mg/ml [152 ^M]) in the coronary arterial blood in the first minute of reperfusion in group V. Thus, the suppression of radical production by MPG in vivo cannot be ascribed to nonspecific effects of the drug on the spin adducts of PBN. 
Multiple regression analysis and analysis of covariance demonstrated a significant difference (p<0.05) between group V and group VII in both the estimated y values for \=0 (y intercepts) and the estimated y values for x.=I6
(which corresponds to average collateral flow in the two groups).
Phase C: Effects of MPG In Vitro
Effect on • Oj. A mixture of hypoxanthine and xanthine oxidase at pH 7.4 was used to generate • Oj, which was measured by its ability to reduce cytochrome c 34 or NBT. 35 MPG (1.5 raM final concentration) did not decrease the rate of reduction of 100 fjM cytochrome c by this system (MPG at this concentration did not reduce cytochrome c directly under our experimental conditions, although higher concentrations did have this effect). MPG (3 mM final concentration) had no significant effect on the rate of NBT reduction; there was no observable direct reduction of NBT by MPG. Under our reaction conditions, cytochrome c reacts with • Oj with a second-order rate constant of approximately 2.6X10 3 M"'sec" 136 and NBT reacts with a rate constant of about 6x 10 4 M^sec" 1 . 37 The inability of MPG, at concentrations 15 times greater than those of cytochrome c or 30 times greater than those of NBT, to decrease the rates of cytochrome c or NBT reduction suggests that the reaction of MPG with • Oi, if any, is very slow, proceeding with a rate constant <10 3 M"'sec~'.
Effect on Hfi 2 . The rate of reaction of MPG with H2O2 w a s followed as the loss of the -SH group, using DTNB. 38 Initial experiments showed that when MPG (final concentration 0.24-2.4 mM) was incubated with H 2 O 2 (10.6 mM final concentration) at 37° C, the initial rate of loss of thiol was proportional to the concentration of MPG. For example, Figure 5 shows the rate of loss of MPG upon incubation with 10 mM H 2 O 2 at 37° C. A secondorder rate constant of approximately 1.6 M"'sec"' was calculated from the combined data of nine experiments. Hence, MPG does react slowly with H 2 O 2 , but the very small rate constant for this reaction suggests that it may not be significant at the low (micromolar) concentrations of H 2 O 2 likely to be present in vivo.
Effect on • OH. Radiolysis of a dilute (10 mM) phosphate-buffered (pH 7.0) solution saturated with nitrous oxide produces • OH. If KCNS is added to the solution, • OH reacts with the thiocyanate ion (SCN ) to produce an absorbance change. 39 By observing the ability of MPG to compete with SCN" for • OH and so decrease the absorbance changes observed, a rate constant for the reaction of MPG with • OH can be calculated. Figure 6 shows that MPG is an excellent scavenger of • OH; a rate constant (as the mean of three values that differed by <10%) of 8.1x10' M-'sec" 1 was calculated.
Effect on lipid peroxidation. MPG, at concentrations up to 500 fiM, had no inhibitory effect on iron-stimulated peroxidation in rat liver microsomes or liposomes made from extracted ox brain phospholipids. It is known that • OH radicals are not involved in this stimulation of peroxidation by iron. 32 ' 40 
Discussion
This study demonstrates that a substantial portion (apparently most) of the cellular damage responsible for myocardial stunning after reversible ischemia develops in the initial seconds of reperfusion. The study further demonstrates that production of free radicals immediately after reflow is necessary for severe stunning to develop. The antioxidant agent MPG enhanced recovery of function to a similar extent when it was administered before ischemia (group I) or immediately before reperfusion (group II). However, no functional improvement was observed when MPG was administered 1 minute after reperfusion (group III). Further, the enhancement of functional recovery effected by MPG given immediately before reperfusion (group II) was associated with marked suppression of free radical production in vivo during the initial seconds of reflow (group V). The failure of MPG given 1 minute after reperfusion to improve functional recovery (group III) was associated with a delay in the suppression of free radical production, such that the initial reflow-induced burst was unaffected (group VI). Finally, at the concentrations estimated to be attained in vivo, MPG was found to be an exceptionally powerful scavenger of • OH in vitro, as shown by the definitive technique of pulse radiolysis. Taken together, these results provide strong evidence that the phenomenon of myocardial stunning is, at least in part, a form of oxyradicalmediated "reperfusion injury."
Previous investigations have indirectly suggested that oxygen radicals contribute to the genesis of myocardial stunning after reversible ischemia. 8 -14 The present study expands our understanding of the mechanism responsible for this contractile abnormality in two major ways: 1) it identifies a narrow time window (first 60 seconds of reperfusion) during which most of the injury responsible for stunning apparently develops, and 2) it provides direct, in vivo evidence that this reperfusion-associated injury is caused by free radical species (i.e., the data establish a link in the intact animal between the intensity of reflow-induced free radical reactions and the intensity of subsequent contractile derangements).
In recent years, the relative roles of ischemiaassociated versus reperfusion-associated damage have been the subject of intense investigation and debate. Our results indicate that after an episode of brief, reversible ischemia, the myocardium undergoes extensive additional injury upon restoration of flow. Insofar as contractile function is concerned, such injury appears to be a major component of the total damage. Since it is unlikely that our dose of MPG prevented all of the injury associated with reperfusion, the actual magnitude of such injury is probably greater than that which can be inferred from our results. Precise definition of the relative magnitudes of ischemic damage versus reperfusion damage is difficult; nevertheless, if significant oxidative injury preventable by MPG had developed during ischemia, it should have been detected with our experimental protocol. In group I, MPG was given via the intracoronary route for 15 minutes before LAD occlusion and throughout occlusion; this should have resulted in high local MPG concentrations for the entire duration of the ischemic period. Since in group II the infusion of MPG was begun 1 minute before reperfusion, the local MPG concentrations at the time of reflow in these dogs were probably lower than those attained at the same time point in group I. In spite of this, the enhancement of functional recovery in the two groups was similar (Figure 1) , that is, no additional benefit was achieved by administration of MPG during ischemia. On the other hand, a delay in the administration of MPG of only 2 minutes (i.e., starting the infusion 1 minute after reperfusion [group III]) resulted in complete loss of protection. These observations indicate that the beneficial effects of MPG in groups I and II were entirely due to protection against a tissue injury that developed within the first 60 seconds of reperfusion.
On the basis of these findings, we propose that the prolonged depression of contractility (or "stunning") observed after brief, reversible ischemia is caused to a significant extent-and possibly in large part-by cellular perturbations associated with restoration of flow. We further propose that such reperfusion-associated injury develops very rapidly, like a burst, immediately after flow is restored.
Our results do not rule out the possibility that additional oxidative injury not preventable by MPG took place during ischemia. However, two considerations suggest that if this were the case, the magnitude of such injury would be relatively small. First, 4 hours after reflow, the difference in wall thickening between group II and controls (group IV) corresponded to -75% of baseline values ( Figure 1) ; thus, MPG given at reperfusion prevented most of the postischemic depression of contractility. Second, the difference in wall thickening between groups II and IV was equivalent to or greater than that observed between treated and control dogs when antioxidant agents were administered before ischemia. 8.11-14,19 of course, it is also possible-indeed likely-that other mecha-nism^) of injury independent of free radicals develop during ischemia/reperfusion. 7 Considerable evidence now suggests that altered calcium homeostasis plays an important role in myocardial stunning. 41 -43 Whether or not this abnormality is related to free radicals remains to be established, but the possibility exists that oxyradical-mediatcd damage and impaired calcium handling represent two steps of the same pathogenetic sequence. 7 -44 Our data provide the first demonstration that MPG suppresses production of free radicals in the intact animal. The efficacy of the drug, given just before reperfusion, in reducing formation of radical species in the stunned myocardium was striking ( Figure 3) . Accordingly, the present study identifies an antioxidant that has the potential to be highly effective in mitigating the radical-mediated injury associated with reperfusion.
Aside from any therapeutic application, the foregoing findings have important implications. Previous studies have shown that free radicals are generated in the stunned myocardium in the intact animal. 19 However, the fundamental question remains: are these species actually responsible for the contractile abnormality? To gain insights into this problem it is necessary to manipulate free radical formation and to assess the effects on contractility: if free radicals indeed play a causal role in myocardial stunning, then blocking their production should result in enhanced recovery of function. Unfortunately, this has not been demonstrated in vivo. The inability to establish an unambiguous link in vivo between attenuation of radical reactions and attenuation of myocardial stunning has been one of the major reasons for the uncertainty that continues to surround the free radical hypothesis. 7 The present study demonstrates that radical generation in the stunned myocardium (group VII) is associated with mechanical dysfunction (group IV), and that suppression of early radical generation (group V) results in attenuation of mechanical dysfunction (group II). Therefore, radical generation is not only associated with, but also necessary for, the development of myocardial stunning. These observations suggest that free radical species play a causal role in the depression of contractility and provide new direct evidence supporting the oxyradical hypothesis.
The present study further shows that when antioxidant therapy is delayed until 1 minute after reflow, radical generation during the rest of the reperfusion phase can still be suppressed (group VI) but mechanical dysfunction is not attenuated (group III). Thus, once the initial burst of free radical reactions has occurred, inhibition of subsequent radical production does not reverse or mitigate the damage caused by that burst, at least over a 4-hour period. This observation suggests that the free radicals critical in the pathogenesis of myocardial stunning are those produced immediately after restoration of flow.
Despite the fact that in group VI MPG was started after the cascade of free radical reactions had been triggered, the drug caused an immediate decrease in production of PBN-trapped radicals to values that were no longer statistically different from group V (Figure 3 ). The slight lag between the time when MPG was started and the time when PBN adduct production became actually equal to group V (10 minutes postreperfusion) may be due to several factors. As discussed below, it is likely that MPG acted by scavenging • OH and thereby preventing • OH-initiated reactions such as lipid peroxidation; on the other hand, the radicals trapped by PBN are likely to be byproducts of lipid peroxidation. Since in group VI oxyradical production occurred undisturbed for the first 60 seconds of reperfusion, and since oxyradical-initiated lipid peroxidation is a self-propagating process that can continue even after the production of the initiating radicals has ceased, 44 one would not expect MPG to cause an immediate complete cessation of PBN adduct production. In addition, it is possible that PBN adducts continue to appear in the local venous blood for a few minutes after their production stops.
After establishing the ability of MPG to inhibit free radical reactions in vivo, we sought to elucidate the mechanism of action of this thiol compound. We found that MPG is an extremely potent scavenger of • OH, reacting with this radical at nearly diffusioncontrolled rates (rate constant=8.1xl0 9 M"'sec" 1 ). (For comparison, mannitol, a commonly used • OH scavenger, reacts more slowly with • OH under the same conditions [rate constant=2.7x 10 9 M~'sec~1] 45 .) MPG effectively scavenged • OH in vitro at concentrations (100 fiM) lower than those estimated to be present in vivo in the coronary arterial inflow during the initial, critical 60 seconds of reperfusion (152 (±M [24.8 jig/ml]). In contrast, under our experimental conditions, we could find no evidence for a reaction of MPG with the • O 2 radical. Even at concentrations (3 mM) 20 times greater than those estimated in vivo (152 MM), MPG exhibited essentially no • Ofscavenging properties in vitro. The reaction of MPG with • Oj may be slower than our techniques allow us to estimate (i.e., the rate constant may be <10 3 M~1sec" 1 ), but in this case it would be unlikely to be biologically significant because it would be slower than the nonenzymatic dismutation of • Oj. 36 -37 We found that MPG does react slowly with H 2 O 2 ( Figure  5) ; however, because of the extremely low rate constant (1.6 M^'sec" 1 ), this effect should be negligible at the concentrations of MPG estimated to be present in vivo (-150 fjM). (Indeed, 150 fiM MPG had no effect on H 2 O 2 in vitro.) Although MPG has been previously shown to scavenge hypochlorous acid (HOG), 46 this is unlikely to be an important mechanism of protection in our model because HOC1 is a byproduct of leukocyte-derived myeloperoxidase, and considerable evidence indicates that leukocytes do not play a prominent role in myocardial stunning after 15 minutes of ischemia. 20 -21 -47 - 48 Finally, we found that MPG, in concentrations up to 0.5 mM (which are more than three times higher than the estimated in vivo plasma concentrations [152 /xM]), had no effect on ironstimulated, • OH-independent lipid peroxidation.
In conclusion, our in vitro analysis suggests that scavenging of • OH radicals was the central mechanism whereby MPG attenuated postischemic dysfunction, and thus supports the concept that • OH plays a prominent role in the reperfusion-associated injury responsible for myocardial stunning. This concept is consistent with previous results. 1214 Scavenging of • OH radicals may confer protection through multiple mechanisms, since these species can attack virtually all cellular constituents. 44 Our spin-trapping studies suggest that MPG protected membrane lipids from oxidative damage. As discussed previously, the hyperfine coupling constants of our EPR spectra ( Figure 2) are consistent with the trapping by PBN of a mixture of oxygen-and carboncentered lipid radicals, such as alkoxy and alkyl radicals. 19 It is well known that oxyradical-initiated peroxidation of membrane lipids gives rise to alkoxy as well as alkyl radicals, 44 both of which can be trapped by PBN. 26 The fact that the PBN adducts are soluble in nonaqueous solvents and resemble the lipid radical adducts of PBN observed in other systems 26 further supports the concept that they are derived from membrane lipids. Accordingly, the marked suppression of PBN adduct formation provides evidence that MPG reduced the rate of lipid peroxidation. The ability of MPG to react with • OH in vitro suggests that the drug may be acting to prevent the initiation of the lipid peroxidation pro-cess by • OH; the inability of MPG to interfere with iron-induced, • OH-independent peroxidation in vitro suggests that the drug does not inhibit subsequent steps of the peroxidative process.
MPG was selected for the present study for several reasons. This free radical scavenger readily crosses the cell membrane 49 and, therefore, may protect from oxyradicals generated both in the intracellular and extracellular space. MPG has been shown to reduce myocardial infarct size 50 -51 and to protect against a number of pathologic processes linked to abnormal free radical production, including inflammation 52^53 and irradiation. 49 Since • OH is the principal oxidizing radical generated by ionizing radiation, 54 protection against radiation provides strong evidence for an • OH-scavenging action of MPG in vivo, in accordance with our in vitro results.
There are numerous clinical settings in which the myocardium is exposed to transient ischemia. 5 Several recent observations suggest that these situations may be associated with myocardial stunning, which may be an important factor precipitating LV failure with its attendant morbidity and mortality. 5 -7 A major problem in the implementation of appropriate treatments is the uncertainty regarding the exact time window during which the critical injury develops and, consequently, antioxidant therapies would be effective. An additional problem is that treatment often cannot be initiated before ischemia. Our results indicating that postischemic dysfunction can be markedly attenuated by antioxidant therapy implemented just before restoration of flow, even in the absence of any treatment during ischemia, should provide a rationale for developing clinically applicable interventions in these situations. Clinical studies have found MPG to be beneficial in the treatment of various disorders linked to abnormal free radical production.52,53,55 The drug has been used clinically in Europe and Japan for nearly two decades and is generally reported to be well tolerated. 52 -55 Therefore, further investigation of this agent appears warranted.
